Search Results - "Aucoin, Nathalie" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

by Renouf, Daniel J, Loree, Jonathan M, Knox, Jennifer J, Topham, James T, Kavan, Petr, Jonker, Derek, Welch, Stephen, Couture, Felix, Lemay, Frederic, Tehfe, Mustapha, Harb, Mohammed, Aucoin, Nathalie, Ko, Yoo-Joung, Tang, Patricia A, Ramjeesingh, Ravi, Meyers, Brandon M, Kim, Christina A, Du, Pan, Jia, Shidong, Schaeffer, David F, Gill, Sharlene, Tu, Dongsheng, O'Callaghan, Chris J
Published in Nature communications (26.08.2022)

Get full text

Journal Article

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial

by Tournigand, Christophe, Prof, Chibaudel, Benoist, MD, Samson, Benoit, MD, Scheithauer, Werner, Prof, Vernerey, Dewi, PhD, Mésange, Paul, PhD, Lledo, Gérard, MD, Viret, Frédéric, MD, Ramée, Jean-François, MD, Tubiana-Mathieu, Nicole, Prof, Dauba, Jérôme, MD, Dupuis, Olivier, MD, Rinaldi, Yves, MD, Mabro, May, MD, Aucoin, Nathalie, MD, Latreille, Jean, MD, Bonnetain, Franck, Prof, Louvet, Christophe, Prof, Larsen, Annette K, PhD, André, Thierry, Prof, de Gramont, Aimery, Prof
Published in The lancet oncology (01.11.2015)

Get full text

Journal Article

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study

by Chen, Eric X, Jonker, Derek J, Loree, Jonathan M, Kennecke, Hagen F, Berry, Scott R, Couture, Felix, Ahmad, Chaudhary E, Goffin, John R, Kavan, Petr, Harb, Mohammed, Colwell, Bruce, Samimi, Setareh, Samson, Benoit, Abbas, Tahir, Aucoin, Nathalie, Aubin, Francine, Koski, Sheryl L, Wei, Alice C, Magoski, Nadine M, Tu, Dongsheng, O'Callaghan, Chris J
Published in JAMA oncology (01.06.2020)

Get more information

Journal Article

Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial

Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial

by Borges, Virginia F, Ferrario, Cristiano, Aucoin, Nathalie, Falkson, Carla, Khan, Qamar, Krop, Ian, Welch, Stephen, Conlin, Alison, Chaves, Jorge, Bedard, Philippe L, Chamberlain, Marc, Gray, Todd, Vo, Alex, Hamilton, Erika
Published in JAMA oncology (01.09.2018)

Get more information

Journal Article

Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial

Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial

by Ma, Lucy Xiaolu, Loree, Jonathan M., Jonker, Derek J., Kennecke, Hagen Fritz, Berry, Scott R., Couture, Felix, Ahmad, Chaudhary E., Goffin, John R., Kavan, Petr, Harb, Mohammed, Colwell, Bruce, Samimi, Setareh, Samson, Benoit, Abbas, Tahir, Aucoin, Nathalie, Aubin, Francine, Koski, Sheryl L., Tu, Dongsheng, O'Callaghan, Christopher J., Chen, Eric X
Published in Journal of clinical oncology (01.06.2023)

Get full text

Journal Article

$Plasma phosphocreatine (PC) as a predictive biomarker for immune checkpoint inhibition in patients with refractory metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial$

Plasma phosphocreatine (PC) as a predictive biomarker for immune checkpoint inhibition in patients with refractory metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial

by Ma, Lucy Xiaolu, Loree, Jonathan M., Jonker, Derek J., Kennecke, Hagen Fritz, Berry, Scott R., Couture, Felix, Ahmad, Chaudhary E., Goffin, John R., Kavan, Petr, Harb, Mohammed, Colwell, Bruce, Samimi, Setareh, Samson, Benoit, Abbas, Tahir, Aucoin, Nathalie, Aubin, Francine, Koski, Sheryl L., Tu, Dongsheng, O'Callaghan, Christopher J., Chen, Eric Xueyu
Published in Journal of clinical oncology (01.02.2023)

Get full text

Journal Article

$Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26$

Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26

by Chen, Eric Xueyu, Loree, Jonathan M., Tu, Dongsheng, O'Callaghan, Christopher J., Kennecke, Hagen Fritz, Jonker, Derek J., Chaudhary, Ahmad, Colwell, Bruce, Harb, Mohammed, Aucoin, Nathalie, Couture, Felix, Samimi, Setareh, Kavan, Petr, Aubin, Francine, Samson, Benoit, Goffin, John R., Berry, Scott, Abbas, Tahir, Koski, Sheryl L., Wei, Alice Chia-chi
Published in Journal of clinical oncology (01.06.2022)

Get full text

Journal Article

Predictive value of germline ATM mutations in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D) and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

Predictive value of germline ATM mutations in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D) and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

by Renouf, Daniel John, Loree, Jonathan M., Knox, Jennifer J., Kavan, Petr, Jonker, Derek J., Welch, Stephen, Couture, Felix, Lemay, Frederic, Tehfe, Mustapha, Harb, Mohammed, Aucoin, Nathalie, Ko, Yoo-Joung, Tang, Patricia A., Topham, James T., Jia, Shidong, Du, Pan, Schaeffer, David F., Gill, Sharlene, Tu, Dongsheng, O'Callaghan, Christopher J.
Published in Journal of clinical oncology (20.05.2021)

Get full text

Journal Article

Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

by Renouf, Daniel John, Loree, Jonathan M., Knox, Jennifer J., Kavan, Petr, Jonker, Derek J., Welch, Stephen, Couture, Felix, Lemay, Frederic, Tehfe, Mustapha, Harb, Mohammed, Aucoin, Nathalie, Ko, Yoo-Joung, Tang, Patricia A., Topham, James T., Jia, Shidong, Du, Pan, Schaeffer, David F., Gill, Sharlene, Tu, Dongsheng, O'Callaghan, Christopher J.
Published in Journal of clinical oncology (20.01.2021)

Get full text

Journal Article

Clinical benefit of tucatinib after isolated brain progression: A retrospective pooled analysis of tucatinib phase 1b studies in HER2+ breast cancer

Clinical benefit of tucatinib after isolated brain progression: A retrospective pooled analysis of tucatinib phase 1b studies in HER2+ breast cancer

by Murthy, Rashmi Krishna, Hamilton, Erika Paige, Ferrario, Cristiano, Aucoin, Nathalie, Falkson, Carla Isadora, Chamberlain, Marc C., Gray, Todd, Borges, Virginia F.
Published in Journal of clinical oncology (20.05.2018)

Get full text

Journal Article

Patterns in KRAS testing and EGFRi therapy across lines of treatment for metastatic colorectal cancer in Canada: A retrospective analysis

Patterns in KRAS testing and EGFRi therapy across lines of treatment for metastatic colorectal cancer in Canada: A retrospective analysis

by Kennecke, Hagen F., Maroun, Jean Alfred, Kavan, Petr, Aucoin, Nathalie, Couture, Felix, Poulin-Costello, Melanie, Gillesby, Brad, Berry, Scott R.
Published in Journal of clinical oncology (01.02.2016)

Get full text

Journal Article

$CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC)$

CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC)

by Chen, Eric Xueyu, Jonker, Derek J., Loree, Jonathan M., Kennecke, Hagen F., Berry, Scott R., Couture, Felix, Ahmad, Chaudhary E., Goffin, John R., Kavan, Petr, Harb, Mohammed, Colwell, Bruce, Samimi, Setareh, Samson, Benoit, Abbas, Tahir, Aucoin, Nathalie, Aubin, Francine, Koski, Sheryl L., Wei, Alice Chia-chi, Tu, Dongsheng, O'Callaghan, Christopher J.
Published in Journal of clinical oncology (20.05.2019)

Get full text

Journal Article

$CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC)$

CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC)

by Chen, Eric Xueyu, Jonker, Derek J., Kennecke, Hagen F., Berry, Scott R., Couture, Felix, Ahmad, Chaudhary E., Goffin, John R., Kavan, Petr, Harb, Mohammed, Colwell, Bruce, Samimi, Setareh, Samson, Benoit, Abbas, Tahir, Aucoin, Nathalie, Aubin, Francine, Koski, Sheryl L., Wei, Alice Chia-chi, Magoski, Nadine M, Tu, Dongsheng, O'Callaghan, Christopher J.
Published in Journal of clinical oncology (01.02.2019)

Get full text

Journal Article

$Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial$

Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial

by Chen, Eric X, Loree, Jonathan M, Titmuss, Emma, Jonker, Derek J, Kennecke, Hagen F, Berry, Scott, Couture, Felix, Ahmad, Chaudharry E, Goffin, John R, Kavan, Petr, Harb, Mohammed, Colwell, Bruce, Samimi, Setareh, Samson, Benoit, Abbas, Tahir, Aucoin, Nathalie, Aubin, Francine, Koski, Sheryl, Wei, Alice C, Tu, Dongsheng, O'Callaghan, Chris J
Published in JAMA network open (01.12.2023)

Get full text

Journal Article

Abstract P4-15-08: A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC)

Abstract P4-15-08: A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC)

by Borges, Virginia F, Hamilton, Erika, Yardley, Denise A, Chaves, Jorge, Aucoin, Nathalie, Ferrario, Cristiano, Walker, Luke, Krop, Ian
Published in Cancer research (Chicago, Ill.) (01.05.2015)

Get full text

Journal Article

Impact of primary tumor sidedness on erlotinib efficacy in patients with metastatic colorectal cancer treated with bevacizumab maintenance: Results from the DREAM phase III trial

Impact of primary tumor sidedness on erlotinib efficacy in patients with metastatic colorectal cancer treated with bevacizumab maintenance: Results from the DREAM phase III trial

by Chibaudel, Benoist, Andre, Thierry, Samson, Benoit, Garcia-Larnicol, Marie-Line, Dauba, Jérôme, Lledo, Gerard, Dupuis, Olivier Jean Marie, Rinaldi, Yves, Mabro, May, Aucoin, Nathalie, Viret, Frédéric, Tubiana-Mathieu, Nicole, Khalil, Ahmed, Baba Hamed, Ghaouti Nabil, Scheithauer, Werner, Carola, Elisabeth, Vernerey, Dewi, Louvet, Christophe, De Gramont, Aimery, Tournigand, Christophe
Published in Journal of clinical oncology (01.02.2018)

Get full text

Journal Article

Efficacy results of a phase 1b study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases

Efficacy results of a phase 1b study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases

by Borges, Virginia F., Ferrario, Cristiano, Aucoin, Nathalie, Falkson, Carla Isadora, Khan, Qamar J., Krop, Ian E., Welch, Stephen, Bedard, Philippe L., Conlin, Alison Katherine, Chaves, Jorge, Walker, Luke N., Hamilton, Erika Paige
Published in Journal of clinical oncology (20.05.2016)

Get full text

Journal Article

Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi)

Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi)

by Saad, Fred, Winquist, Eric, Hubay, Stacey, Berry, Scott R., Assi, Hazem, Levesque, Eric, Aucoin, Nathalie, Czaykowski, Piotr, Lattouf, Jean-Baptiste, Alloul, Karine, Stewart, John, Sridhar, Srikala S.
Published in Journal of clinical oncology (20.05.2014)

Get full text

Journal Article

Cabazitaxel in docetaxel-pretreated metastatic castration resistant prostate cancer (mCRPC): Canadian experience

Cabazitaxel in docetaxel-pretreated metastatic castration resistant prostate cancer (mCRPC): Canadian experience

by Sridhar, Srikala S., Winquist, Eric, Hubay, Stacey, Assi, Hazem, Berry, Scott R., Stewart, John, Levesque, Eric, Aucoin, Nathalie, Czaykowski, Piotr, Saad, Fred
Published in Journal of clinical oncology (20.05.2013)

Get full text

Journal Article

Quality of life (QoL) of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel

Quality of life (QoL) of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel

by Winquist, Eric, Sridhar, Srikala S., Hubay, Stacey, Assi, Hazem, Berry, Scott R., Alloul, Karine, Levesque, Eric, Aucoin, Nathalie, Czaykowski, Piotr, Saad, Fred
Published in Journal of clinical oncology (20.05.2013)

Get full text

Journal Article